U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Bladder Carcinoma

MedGen UID:
1664919
•Concept ID:
C4725675
•
Neoplastic Process

Definition

Bladder carcinoma that does not respond to treatment. [from NCI]

Professional guidelines

PubMed

Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities.
Mahmoud AM, Nabavizadeh R, Rodrigues Pessoa R, Garg I, Orme J, Costello BA, Cheville J, Lucien F
Oncologist 2023 Apr 6;28(4):297-308. doi: 10.1093/oncolo/oyac263. PMID: 36745503Free PMC Article
Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review.
Yang HY, Wu CY, Chen JJ, Lee TH
Int J Mol Sci 2020 Nov 26;21(23) doi: 10.3390/ijms21238993. PMID: 33256165Free PMC Article
Erdafitinib for the treatment of metastatic bladder cancer.
Montazeri K, Bellmunt J
Expert Rev Clin Pharmacol 2020 Jan;13(1):1-6. Epub 2019 Dec 22 doi: 10.1080/17512433.2020.1702025. PMID: 31810398

Recent clinical studies

Etiology

Identification of SKOR2 IgG as a novel biomarker of paraneoplastic neurologic syndrome.
Rezk M, Pittock SJ, Kapadia RK, Knight AM, Guo Y, Gupta P, LaFrance-Corey RG, Zekeridou A, McKeon A, Dasari S, Mills JR, Dubey D
Front Immunol 2023;14:1243946. Epub 2023 Sep 18 doi: 10.3389/fimmu.2023.1243946. PMID: 37795104Free PMC Article
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH
Ann Oncol 2023 Mar;34(3):289-299. Epub 2022 Dec 6 doi: 10.1016/j.annonc.2022.11.012. PMID: 36494006
Role of immunotherapy in bladder cancer.
Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB
Cancer Treat Res Commun 2021;26:100296. Epub 2020 Dec 24 doi: 10.1016/j.ctarc.2020.100296. PMID: 33421822
Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.
Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA
J Clin Oncol 2016 Jun 1;34(16):1935-44. Epub 2016 Jan 25 doi: 10.1200/JCO.2015.64.4070. PMID: 26811532Free PMC Article
Radical cystectomy and the implications of comorbidity.
Mayr R, Fritsche HM, Pycha A, Pycha A
Expert Rev Anticancer Ther 2014 Mar;14(3):289-95. Epub 2014 Jan 8 doi: 10.1586/14737140.2014.868775. PMID: 24397794

Diagnosis

Identification of SKOR2 IgG as a novel biomarker of paraneoplastic neurologic syndrome.
Rezk M, Pittock SJ, Kapadia RK, Knight AM, Guo Y, Gupta P, LaFrance-Corey RG, Zekeridou A, McKeon A, Dasari S, Mills JR, Dubey D
Front Immunol 2023;14:1243946. Epub 2023 Sep 18 doi: 10.3389/fimmu.2023.1243946. PMID: 37795104Free PMC Article
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY
Eur Urol Oncol 2022 Dec;5(6):714-718. Epub 2022 Feb 23 doi: 10.1016/j.euo.2021.11.005. PMID: 35216942Free PMC Article
Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.
Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J
Clin Cancer Res 2021 Sep 15;27(18):5123-5130. Epub 2021 Jun 9 doi: 10.1158/1078-0432.CCR-20-4175. PMID: 34108177Free PMC Article
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A, Guo J
Clin Cancer Res 2021 Jan 1;27(1):43-51. Epub 2020 Oct 27 doi: 10.1158/1078-0432.CCR-20-2488. PMID: 33109737
Localized bladder cancer.
Izawa JI, Grossman HB
Curr Treat Options Oncol 2000 Dec;1(5):423-32. doi: 10.1007/s11864-000-0070-5. PMID: 12057150

Therapy

Novel uses of complement inhibitors in myasthenia gravis-Two case reports.
Zadeh S, Price H, Drews R, Bouffard MA, Young LH, Narayanaswami P
Muscle Nerve 2024 Mar;69(3):368-372. Epub 2024 Jan 11 doi: 10.1002/mus.28037. PMID: 38205840
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH
Ann Oncol 2023 Mar;34(3):289-299. Epub 2022 Dec 6 doi: 10.1016/j.annonc.2022.11.012. PMID: 36494006
Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
Peng J, Sridhar S, Siefker-Radtke AO, Selvarajah S, Jiang DM
Curr Treat Options Oncol 2022 Sep;23(9):1269-1287. Epub 2022 Aug 13 doi: 10.1007/s11864-022-01009-4. PMID: 35962938
Role of immunotherapy in bladder cancer.
Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB
Cancer Treat Res Commun 2021;26:100296. Epub 2020 Dec 24 doi: 10.1016/j.ctarc.2020.100296. PMID: 33421822
Farnesyltransferase inhibitors.
Sebti SM, Adjei AA
Semin Oncol 2004 Feb;31(1 Suppl 1):28-39. doi: 10.1053/j.seminoncol.2003.12.012. PMID: 14981578

Prognosis

Identification of SKOR2 IgG as a novel biomarker of paraneoplastic neurologic syndrome.
Rezk M, Pittock SJ, Kapadia RK, Knight AM, Guo Y, Gupta P, LaFrance-Corey RG, Zekeridou A, McKeon A, Dasari S, Mills JR, Dubey D
Front Immunol 2023;14:1243946. Epub 2023 Sep 18 doi: 10.3389/fimmu.2023.1243946. PMID: 37795104Free PMC Article
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar AV, Castellano DE, Grivas P, Vaughn DJ, Powles T, Vuky J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Necchi A, Petrylak DP, Plimack ER, Xu JZ, Imai K, Moreno BH, Bellmunt J, de Wit R, O'Donnell PH
Ann Oncol 2023 Mar;34(3):289-299. Epub 2022 Dec 6 doi: 10.1016/j.annonc.2022.11.012. PMID: 36494006
Radical cystectomy and the implications of comorbidity.
Mayr R, Fritsche HM, Pycha A, Pycha A
Expert Rev Anticancer Ther 2014 Mar;14(3):289-95. Epub 2014 Jan 8 doi: 10.1586/14737140.2014.868775. PMID: 24397794
Novel strategies for treating relapsed/refractory urothelial carcinoma.
Iyer G, Milowsky MI, Bajorin DF
Expert Rev Anticancer Ther 2010 Dec;10(12):1917-32. doi: 10.1586/era.10.182. PMID: 21110758Free PMC Article
Localized bladder cancer.
Izawa JI, Grossman HB
Curr Treat Options Oncol 2000 Dec;1(5):423-32. doi: 10.1007/s11864-000-0070-5. PMID: 12057150

Clinical prediction guides

Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, Yao X, Shi B, Liu J, Hu C, Liu Z, Guo H, Yu G, Ji Z, Ying J, Ling Y, Yu S, Hu Y, Guo J, Fang J, Zhou A, Guo J
J Clin Oncol 2024 Apr 20;42(12):1391-1402. Epub 2023 Nov 21 doi: 10.1200/JCO.22.02912. PMID: 37988648Free PMC Article
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
Komura K, Tokushige S, Ishida M, Hirosuna K, Yamazaki S, Nishimura K, Ajiro M, Ohno T, Nakamori K, Kinoshita S, Tsujino T, Maenosono R, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H
Cancer Sci 2023 Dec;114(12):4622-4631. Epub 2023 Sep 26 doi: 10.1111/cas.15976. PMID: 37752769Free PMC Article
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies.
Lui G, Minnar CM, Soon-Shiong P, Schlom J, Gameiro SR
Cells 2023 Jun 12;12(12) doi: 10.3390/cells12121611. PMID: 37371081Free PMC Article
Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs.
Lu X, Lu X
Biochim Biophys Acta Rev Cancer 2022 May;1877(3):188702. Epub 2022 Feb 25 doi: 10.1016/j.bbcan.2022.188702. PMID: 35227829Free PMC Article
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS
Cancer 2022 Mar 15;128(6):1194-1205. Epub 2021 Dec 9 doi: 10.1002/cncr.34057. PMID: 34882781

Recent systematic reviews

Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Tafuri A, Smith DD, Cacciamani GE, Cole S, Shakir A, Sadeghi S, Vogelzang NJ, Quinn D, Gill PS, Gill IS
Clin Genitourin Cancer 2020 Oct;18(5):351-360.e3. Epub 2020 Jan 31 doi: 10.1016/j.clgc.2020.01.004. PMID: 32146152Free PMC Article
Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
Hwang EC, Sathianathen NJ, Imamura M, Kuntz GM, Risk MC, Dahm P
Cochrane Database Syst Rev 2019 May 14;5(5):CD013336. doi: 10.1002/14651858.CD013336. PMID: 31111956Free PMC Article
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF, Kulkarni GS
Eur Urol 2018 Nov;74(5):597-608. Epub 2018 Jul 13 doi: 10.1016/j.eururo.2018.06.024. PMID: 30017405
Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD, Jones G, Cleves A, Wilt TJ, Mason MD, Kynaston HG
BJU Int 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x. PMID: 22313502

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...